Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled 510 patients with ... in acute pain, with Vertex Pharma filing for approval ...
As of 7 March at 10:00:11 GMT-5. Market open. Vertex Baseline Delta ...
As of 7 March at 10:00:11 am GMT-5. Market open. Vertex Baseline Delta ...
As of 10 March at 3:43:31 pm GMT-4. Market open. Vertex Baseline Delta ...
As of 10 February at 9:46:03 am GMT-5. Market open. Vertex Baseline Delta ...
As of 20 February at 3:50:01 pm GMT-5. Market open. Vertex Baseline Delta ...
As of 19 February at 10:36:00 GMT-5. Market open. Vertex Baseline Delta ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback